Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure - 21/08/11
, Lyle J. Olson, MD a, Diane Grill, MS b, Soundos K. Moualla, MD a, Susan M. Nelson, LPN a, Thomas P. Nobrega, MD a, Richard D. Hanna, MD c, Richard J. Backes, MD d, Farouk Mookadam, MD a, Denise Heublein, MD a, Kent R. Bailey, PhD b, John C. Burnett, MD aRésumé |
Background |
β-Blocker therapy improves symptoms, left ventricular ejection fraction (LVEF), and survival in patients with congestive heart failure, but chronic effects on neurohormones have not been extensively investigated. Therefore, we examined the neurohumoral effects of carvedilol.
Methods |
Fifty-five patients with New York Heart Association (NYHA) classes II-III congestive heart failure and LVEF ≤35% entered the study with intention to assess LVEF, NYHA class, plasma brain natriuretic peptide (BNP), N-terminal atrial natriuretic peptide (NANP), big-endothelin, endothelin-1, norepinephrine, and angiotensin II at baseline and at 6 and 12 months after initiation of carvedilol.
Results |
Forty-six patients completed 12 months of follow-up. Left ventricular ejection fraction improved from 26% ± 8% at baseline to 39% ± 14% at 12 months. New York Heart Association class improved from 2.3 ± 0.4 at baseline to 1.8 ± 0.7 at 12 months. Brain natriuretic peptide fell from 453 ± 784 to 208 ± 393 pg/mL at 6 months and 223 ± 334 pg/mL at 12 months (P = .01 vs baseline). N-terminal atrial natriuretic peptide did not change between baseline and 6 months but fell at 12 months (2117 ± 1678, 2015 ± 1532, and 1438 ± 1442 pg/mL, respectively, P = .001 between baseline and 12 months). Angiotensin II was lower at 6 and 12 months than at baseline (12.6 ± 10, 7.8 ± 5.5 pg/mL, P < 0.001, and 11.3 ± 17.1 pg/mL, P = .02, respectively). Left ventricular ejection fraction at 12 months correlated inversely with BNP level at 12 months (r = −0.55, P = .001).
Conclusions |
Carvedilol therapy is associated with a sustained decline in BNP and NANP levels. Serial BNP levels can provide some guidance regarding probability of LVEF improvement, but the relationship is not strong enough for BNP levels to supplant measurement of LVEF.
Le texte complet de cet article est disponible en PDF.Plan
| Research Support: Funded by a grant from GlaxoSmithKline to RPF |
Vol 149 - N° 3
P. 541-547 - mars 2005 Retour au numéro
Article précédent
- Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting
- Vivek Rajagopal, Hitinder S. Gurm, Richard C. Brunken, Claire E. Pothier, Deepak L. Bhatt, Michael S. Lauer
- Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)
- Aldo P. Maggioni, Roberto Latini, Peter E. Carson, Steven N. Singh, Simona Barlera, Robert Glazer, Serge Masson, Elisabetta Cerè, Gianni Tognoni, Jay N. Cohn, for the Val-HeFT Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?